Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9843094 | 0.93 | LMNA (0.46) | LMNACYP2C19HIF1ATYMP | |
| Malonic Acid SCHEMBL11132766 | 0.93 | LMNA (0.48) | LMNACYP2C19HIF1ATYMP | |
| SCHEMBL9787640 | 0.92 | LMNA (0.55) | LMNACYP2C19HIF1ATYMPPDE10A | |
| SCHEMBL19261486 | 0.91 | LMNA (0.47) | LMNACYP2C19HIF1ATYMP | |
| Adipic Acid SCHEMBL11497321 | 0.91 | LMNA (0.44) | LMNACYP2C19HIF1ATYMP | |
| SCHEMBL11202227 | 0.89 | LMNA (0.43) | LMNACYP2C19HIF1ATYMP | |
| SCHEMBL11291943 | 0.89 | LMNA (0.51) | LMNACYP2C19HIF1ATYMPPDE10A | |
| SCHEMBL1389273 | 0.88 | LMNA (0.67) | LMNACYP2C19HIF1ATYMPPDE10A | |
| SCHEMBL11209816 | 0.88 | LMNA (0.43) | LMNACYP2C19HIF1ATYMP | |
| SCHEMBL11207689 | 0.87 | LMNA (0.42) | LMNACYP2C19HIF1ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073356-A1 | REACTIVE MULTI-ARM POLYMERS HAVING BRANCHED END GROUPS | BOSTON SCIENT SCIMED INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12178888-B2 | Reactive multi-arm polymers having branched end groups | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4021960-A1 | REACTIVE MULTI-ARM POLYMERS HAVING BRANCHED END GROUPS | Boston Scientific Scimed Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114269393-A | Reactive multiarm polymers with branched end groups | 波士顿科学医学有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210060183-A1 | REACTIVE MULTI-ARM POLYMERS HAVING BRANCHED END GROUPS | BOSTON SCIENTIFIC SCIMED, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2021041234-A1 | REACTIVE MULTI-ARM POLYMERS HAVING BRANCHED END GROUPS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-9738596-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2017-08-22 | — | — | US | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079201-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010060941-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060941-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-06-03 | — | — | WO | disclosed |
| EP-2178568-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008734-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191422-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.